A novel approach for estimating vaccine efficacy for infections with multiple disease outcomes: application to a COVID-19 vaccine trial
Williams, L. R.; Voysey, M.; Pollard, A. J.; Grassly, N. C.
Show abstract
Vaccines can provide protection against infection or limit disease progression and severity. Vaccine efficacy (VE) is typically evaluated independently for different outcomes, but this can cause biased estimates of VE. We propose a new analytical framework based on a model of disease progression for VE estimation for infections with multiple possible outcomes of infection: Joint analysis of multiple outcomes in vaccine efficacy trials (JAMOVET). JAMOVET is a Bayesian hierarchical regression model that controls for biases and can evaluate covariates for VE, the risk of infection, and the probability of progression. We applied JAMOVET to simulated data, and data from COV002 (NCT04400838), a phase 2/3 trial of ChAdOx1 nCoV-19 (AZD1222) vaccine. Simulations showed that biases are corrected by explicitly modelling disease progression and imperfect test characteristics. JAMOVET estimated ChAdOx1 nCoV-19 VE against infection (VEin) at 49% (95% CI 37-59) and progression to symptoms (VEpr) at 44% (95% CI 27-58). This implies a VE against symptomatic infection of 72% (95% CI 63-80), consistent with published trial estimates. VEin decreased with age while VEpr increased with age. JAMOVET is a powerful tool for evaluating diseases with multiple dependent outcomes and can be used to adjust for biases and identify predictors of key outcomes.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel 95%
- Using LASSO regression to estimate the population-level impact of pneumococcal conjugate vaccines 95%
- Estimating the effectiveness of first dose of COVID-19 vaccine against mortality in England: a quasi-experimental study 95%
Similar papers in this journal
- Impact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study 96%
- Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort 95%
- Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study 94%
Similar papers in this journal
- Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness 95%
- Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines 94%
- Incorporating data from multiple endpoints in the analysis of clinical trials: example from RSV vaccines 92%
Similar papers in this journal
- Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study 94%
- SARS-CoV-2 infection risk during delivery of childhood vaccination campaigns: a modelling study 94%
- Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July – November 2021 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.